Diseases /
Acute Myeloid Leukemia
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification). [1]
Acute myeloid leukemias most frequently harbor alterations in NPM1, DNMT3A, ASXL1, TET2, and ETV6 [2].
NPM1 Mutation, NPM1 Exon 12 Mutation, NPM1 W288Cfs*12, DNMT3A Mutation, and ASXL1 Mutation are the most common alterations in acute myeloid leukemia [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for acute myeloid leukemia, 5 are FDA-approved in at least one setting and 5 have NCCN guidelines in at least one setting [3].
Enasidenib +
Disease is predicted to be sensitive: -
Gemtuzumab Ozogamicin +
Disease is predicted to be sensitive: -
Gilteritinib +
Disease is predicted to be sensitive: -
Ivosidenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): First Line of Therapy (FDA), Refractory (FDA, NCCN), Relapse (FDA, NCCN) |
| Note: Approved for adult patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation. |
Midostaurin +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Consolidation Therapy (FDA, NCCN), Treatment Induction (FDA, NCCN) |
| Note: FDA-approved, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation, for adults with newly diagnosed, FLT3-mutated AML. |
Sorafenib +
Disease is predicted to be sensitive: -
Clinical Trials
There are 622 clinical trials for acute myeloid leukemia, of which 461 are open and 161 are completed or closed. Of the trials that contain acute myeloid leukemia as an inclusion criterion, 9 are early phase 1 (7 open), 217 are phase 1 (156 open), 132 are phase 1/phase 2 (100 open), 184 are phase 2 (135 open), 9 are phase 2/phase 3 (6 open), 51 are phase 3 (45 open), 2 are phase 4 (2 open), and 18 are no phase specified (10 open).
FLT3, MECOM, and RPN1 are the most frequent gene inclusion criteria for acute myeloid leukemia clinical trials [3].
Cytarabine, fludarabine, and azacitidine are the most common interventions in acute myeloid leukemia clinical trials.
Significant Genes in Acute Myeloid Leukemia
ABL1 +
ABL1 is altered in 0.41% of acute myeloid leukemia patients [2].
ABL1 is an inclusion eligibility criterion in 117 clinical trials for acute myeloid leukemia, of which 79 are open and 38 are closed. Of the trials that contain ABL1 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (2 open), 31 are phase 1 (16 open), 20 are phase 1/phase 2 (15 open), 50 are phase 2 (37 open), 3 are phase 2/phase 3 (2 open), 8 are phase 3 (6 open), and 3 are no phase specified (1 open) [3].
ABL2 +
ABL2 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain ABL2 status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].
AFF1 +
AFF1 is an inclusion eligibility criterion in 108 clinical trials for acute myeloid leukemia, of which 66 are open and 42 are closed. Of the trials that contain AFF1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 32 are phase 1 (15 open), 16 are phase 1/phase 2 (11 open), 44 are phase 2 (30 open), 2 are phase 2/phase 3 (2 open), 9 are phase 3 (6 open), and 4 are no phase specified (1 open) [3].
ASXL1 +
ASXL1 is altered in 18.18% of acute myeloid leukemia patients [2].
ASXL1 is an inclusion eligibility criterion in 18 clinical trials for acute myeloid leukemia, of which 15 are open and 3 are closed. Of the trials that contain ASXL1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (7 open), 1 is phase 2/phase 3 (0 open), and 1 is phase 3 (1 open) [3].
ATM +
ATM is altered in 2.66% of acute myeloid leukemia patients [2].
ATM is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
BCL2 +
BCL2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCL2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (0 open) [3].
BCL6 +
BCL6 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (0 open) [3].
BCOR +
BCOR is altered in 8.66% of acute myeloid leukemia patients [2].
BCOR is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain BCOR status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
BCR +
BCR is an inclusion eligibility criterion in 116 clinical trials for acute myeloid leukemia, of which 78 are open and 38 are closed. Of the trials that contain BCR status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (2 open), 31 are phase 1 (16 open), 19 are phase 1/phase 2 (14 open), 50 are phase 2 (37 open), 3 are phase 2/phase 3 (2 open), 8 are phase 3 (6 open), and 3 are no phase specified (1 open) [3].
BIRC3 +
BIRC3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
CBFA2T3 +
CBFA2T3 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain CBFA2T3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].
CBFB +
CBFB is an inclusion eligibility criterion in 64 clinical trials for acute myeloid leukemia, of which 29 are open and 35 are closed. Of the trials that contain CBFB status and acute myeloid leukemia as inclusion criteria, 23 are phase 1 (6 open), 7 are phase 1/phase 2 (4 open), 18 are phase 2 (9 open), 3 are phase 2/phase 3 (3 open), 7 are phase 3 (5 open), 1 is phase 4 (1 open), and 5 are no phase specified (1 open) [3].
CBL +
CBL is altered in 2.32% of acute myeloid leukemia patients [2].
CBL is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 1 is open and 1 is closed. Of the trials that contain CBL status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
CEBPA +
CEBPA is altered in 4.03% of acute myeloid leukemia patients [2].
CEBPA is an inclusion eligibility criterion in 11 clinical trials for acute myeloid leukemia, of which 10 are open and 1 is closed. Of the trials that contain CEBPA status and acute myeloid leukemia as inclusion criteria, 6 are phase 2 (5 open), 3 are phase 2/phase 3 (3 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [3].
CREBBP +
CREBBP is altered in 3.19% of acute myeloid leukemia patients [2].
CREBBP is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain CREBBP status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [3].
CRLF2 +
CRLF2 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain CRLF2 status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].
CSF1R +
CSF1R is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain CSF1R status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].
DEK +
DEK is an inclusion eligibility criterion in 104 clinical trials for acute myeloid leukemia, of which 72 are open and 32 are closed. Of the trials that contain DEK status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (2 open), 30 are phase 1 (18 open), 15 are phase 1/phase 2 (10 open), 45 are phase 2 (34 open), 2 are phase 2/phase 3 (1 open), 8 are phase 3 (6 open), and 2 are no phase specified (1 open) [3].
DNMT3A +
DNMT3A is altered in 19.73% of acute myeloid leukemia patients [2].
DNMT3A is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 2 are open and 1 is closed. Of the trials that contain DNMT3A status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].
ELL +
ELL is an inclusion eligibility criterion in 99 clinical trials for acute myeloid leukemia, of which 58 are open and 41 are closed. Of the trials that contain ELL status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 30 are phase 1 (13 open), 16 are phase 1/phase 2 (11 open), 39 are phase 2 (26 open), 1 is phase 2/phase 3 (1 open), 8 are phase 3 (5 open), and 4 are no phase specified (1 open) [3].
EPOR +
EPOR is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain EPOR status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].
ERBB2 +
ERBB2 is altered in 1.07% of acute myeloid leukemia patients [2].
ERBB2 is an inclusion eligibility criterion in 5 clinical trials for acute myeloid leukemia, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (2 open) [3].
ERG +
ERG is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ERG status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
ETV6 +
ETV6 is altered in 16.81% of acute myeloid leukemia patients [2].
ETV6 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain ETV6 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].
EZH2 +
EZH2 is altered in 4.22% of acute myeloid leukemia patients [2].
EZH2 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain EZH2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
FGF2 +
FGF2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGF2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
FGFR3 +
FGFR3 is altered in 1.24% of acute myeloid leukemia patients [2].
FGFR3 is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia, of which 3 are open and 1 is closed. Of the trials that contain FGFR3 status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].
FLT1 +
FLT1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FLT3 +
FLT3 is altered in 11.13% of acute myeloid leukemia patients [2].
FLT3 is an inclusion eligibility criterion in 177 clinical trials for acute myeloid leukemia, of which 121 are open and 56 are closed. Of the trials that contain FLT3 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (2 open), 42 are phase 1 (24 open), 34 are phase 1/phase 2 (23 open), 72 are phase 2 (49 open), 2 are phase 2/phase 3 (1 open), 20 are phase 3 (18 open), and 5 are no phase specified (4 open) [3].
Gilteritinib, midostaurin, and sorafenib have evidence of efficacy in patients with FLT3 mutation in acute myeloid leukemia [3].
FUS +
FUS is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FUS status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
GLIS2 +
GLIS2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains GLIS2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
HIP1 +
HIP1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain HIP1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
HOXA9 +
HOXA9 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains HOXA9 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
HRAS +
HRAS is altered in 2.28% of acute myeloid leukemia patients [2].
HRAS is an inclusion eligibility criterion in 5 clinical trials for acute myeloid leukemia, of which 3 are open and 2 are closed. Of the trials that contain HRAS status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
IDH1 +
IDH1 is altered in 7.95% of acute myeloid leukemia patients [2].
IDH1 is an inclusion eligibility criterion in 13 clinical trials for acute myeloid leukemia, of which 11 are open and 2 are closed. Of the trials that contain IDH1 status and acute myeloid leukemia as inclusion criteria, 4 are phase 1 (3 open), 6 are phase 1/phase 2 (5 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].
Ivosidenib has evidence of efficacy in patients with IDH1 mutation in acute myeloid leukemia [3].
IDH2 +
IDH2 is altered in 10.5% of acute myeloid leukemia patients [2].
IDH2 is an inclusion eligibility criterion in 14 clinical trials for acute myeloid leukemia, of which 13 are open and 1 is closed. Of the trials that contain IDH2 status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open), 5 are phase 1/phase 2 (5 open), 5 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
Enasidenib has evidence of efficacy in patients with IDH2 mutation in acute myeloid leukemia [3].
IGH +
IGH is an inclusion eligibility criterion in 7 clinical trials for acute myeloid leukemia, of which 6 are open and 1 is closed. Of the trials that contain IGH status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].
IKZF1 +
IKZF1 is altered in 1.84% of acute myeloid leukemia patients [2].
IKZF1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 1 is open and 1 is closed. Of the trials that contain IKZF1 status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (1 open) [3].
IL7R +
IL7R is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain IL7R status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].
JAK1 +
JAK1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain JAK1 status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].
JAK2 +
JAK2 is altered in 3.04% of acute myeloid leukemia patients [2].
JAK2 is an inclusion eligibility criterion in 5 clinical trials for acute myeloid leukemia, of which 5 are open and 0 are closed. Of the trials that contain JAK2 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
JAK3 +
JAK3 is altered in 0.44% of acute myeloid leukemia patients [2].
JAK3 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain JAK3 status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].
KAT6A +
KAT6A is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KAT6A status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
KDM5A +
KDM5A is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KDM5A status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
KIT +
KIT is altered in 2.14% of acute myeloid leukemia patients [2].
KIT is an inclusion eligibility criterion in 33 clinical trials for acute myeloid leukemia, of which 22 are open and 11 are closed. Of the trials that contain KIT status and acute myeloid leukemia as inclusion criteria, 11 are phase 1 (6 open), 5 are phase 1/phase 2 (4 open), 11 are phase 2 (8 open), 2 are phase 2/phase 3 (2 open), 3 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
KMT2A +
KMT2A is an inclusion eligibility criterion in 154 clinical trials for acute myeloid leukemia, of which 93 are open and 61 are closed. Of the trials that contain KMT2A status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (2 open), 44 are phase 1 (20 open), 25 are phase 1/phase 2 (18 open), 61 are phase 2 (40 open), 5 are phase 2/phase 3 (4 open), 12 are phase 3 (8 open), and 5 are no phase specified (1 open) [3].
KRAS +
KRAS is altered in 3.87% of acute myeloid leukemia patients [2].
KRAS is an inclusion eligibility criterion in 10 clinical trials for acute myeloid leukemia, of which 5 are open and 5 are closed. Of the trials that contain KRAS status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), 4 are phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].
MAF +
MAF is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain MAF status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].
MAFB +
MAFB is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain MAFB status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
MDM2 +
MDM2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
MDM4 +
MDM4 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
MECOM +
MECOM is an inclusion eligibility criterion in 155 clinical trials for acute myeloid leukemia, of which 117 are open and 38 are closed. Of the trials that contain MECOM status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (2 open), 56 are phase 1 (43 open), 27 are phase 1/phase 2 (19 open), 55 are phase 2 (42 open), 3 are phase 2/phase 3 (2 open), 10 are phase 3 (8 open), and 2 are no phase specified (1 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 68 clinical trials for acute myeloid leukemia, of which 58 are open and 10 are closed. Of the trials that contain MLF1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 31 are phase 1 (26 open), 13 are phase 1/phase 2 (11 open), 18 are phase 2 (16 open), 2 are phase 2/phase 3 (1 open), and 3 are phase 3 (3 open) [3].
MLH1 +
MLH1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
MLH3 +
MLH3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
MLLT1 +
MLLT1 is an inclusion eligibility criterion in 100 clinical trials for acute myeloid leukemia, of which 59 are open and 41 are closed. Of the trials that contain MLLT1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 30 are phase 1 (13 open), 16 are phase 1/phase 2 (11 open), 40 are phase 2 (27 open), 1 is phase 2/phase 3 (1 open), 8 are phase 3 (5 open), and 4 are no phase specified (1 open) [3].
MLLT10 +
MLLT10 is an inclusion eligibility criterion in 99 clinical trials for acute myeloid leukemia, of which 58 are open and 41 are closed. Of the trials that contain MLLT10 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 30 are phase 1 (13 open), 16 are phase 1/phase 2 (11 open), 39 are phase 2 (26 open), 1 is phase 2/phase 3 (1 open), 8 are phase 3 (5 open), and 4 are no phase specified (1 open) [3].
MLLT3 +
MLLT3 is an inclusion eligibility criterion in 114 clinical trials for acute myeloid leukemia, of which 67 are open and 47 are closed. Of the trials that contain MLLT3 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 31 are phase 1 (13 open), 18 are phase 1/phase 2 (12 open), 47 are phase 2 (31 open), 4 are phase 2/phase 3 (3 open), 9 are phase 3 (6 open), and 4 are no phase specified (1 open) [3].
MLLT4 +
MLLT4 is an inclusion eligibility criterion in 101 clinical trials for acute myeloid leukemia, of which 60 are open and 41 are closed. Of the trials that contain MLLT4 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 30 are phase 1 (13 open), 17 are phase 1/phase 2 (12 open), 40 are phase 2 (27 open), 1 is phase 2/phase 3 (1 open), 8 are phase 3 (5 open), and 4 are no phase specified (1 open) [3].
MNX1 +
MNX1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MNX1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
MSH2 +
MSH2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
MSH3 +
MSH3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
MSH6 +
MSH6 is altered in 2.13% of acute myeloid leukemia patients [2].
MSH6 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
MYC +
MYC is altered in 1.77% of acute myeloid leukemia patients [2].
MYC is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 2 are open and 1 is closed. Of the trials that contain MYC status and acute myeloid leukemia as inclusion criteria, 3 are phase 2 (2 open) [3].
MYH11 +
MYH11 is an inclusion eligibility criterion in 64 clinical trials for acute myeloid leukemia, of which 29 are open and 35 are closed. Of the trials that contain MYH11 status and acute myeloid leukemia as inclusion criteria, 23 are phase 1 (6 open), 7 are phase 1/phase 2 (4 open), 18 are phase 2 (9 open), 3 are phase 2/phase 3 (3 open), 7 are phase 3 (5 open), 1 is phase 4 (1 open), and 5 are no phase specified (1 open) [3].
NF1 +
NF1 is altered in 7.45% of acute myeloid leukemia patients [2].
NF1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
NPM1 +
NPM1 is altered in 16.38% of acute myeloid leukemia patients [2].
NPM1 is an inclusion eligibility criterion in 96 clinical trials for acute myeloid leukemia, of which 79 are open and 17 are closed. Of the trials that contain NPM1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 32 are phase 1 (26 open), 18 are phase 1/phase 2 (15 open), 33 are phase 2 (26 open), 5 are phase 2/phase 3 (4 open), 6 are phase 3 (6 open), and 1 is no phase specified (1 open) [3].
NRAS +
NRAS is altered in 9.68% of acute myeloid leukemia patients [2].
NRAS is an inclusion eligibility criterion in 9 clinical trials for acute myeloid leukemia, of which 4 are open and 5 are closed. Of the trials that contain NRAS status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (1 open), 4 are phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].
NSD1 +
NSD1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
NTRK1 +
NTRK1 is altered in 1.77% of acute myeloid leukemia patients [2].
NTRK1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
NUMA1 +
NUMA1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUMA1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 3 (1 open) [3].
NUP214 +
NUP214 is an inclusion eligibility criterion in 104 clinical trials for acute myeloid leukemia, of which 72 are open and 32 are closed. Of the trials that contain NUP214 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (2 open), 30 are phase 1 (18 open), 15 are phase 1/phase 2 (10 open), 45 are phase 2 (34 open), 2 are phase 2/phase 3 (1 open), 8 are phase 3 (6 open), and 2 are no phase specified (1 open) [3].
NUP98 +
NUP98 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
PBX1 +
PBX1 is an inclusion eligibility criterion in 33 clinical trials for acute myeloid leukemia, of which 28 are open and 5 are closed. Of the trials that contain PBX1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 18 are phase 2 (16 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [3].
PDGFRA +
PDGFRA is altered in 0.52% of acute myeloid leukemia patients [2].
PDGFRA is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PDGFRB +
PDGFRB is altered in 2.13% of acute myeloid leukemia patients [2].
PDGFRB is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain PDGFRB status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].
PDS5B +
PDS5B is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDS5B status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
PHF6 +
PHF6 is altered in 4.21% of acute myeloid leukemia patients [2].
PHF6 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
PML +
PML is an inclusion eligibility criterion in 37 clinical trials for acute myeloid leukemia, of which 21 are open and 16 are closed. Of the trials that contain PML status and acute myeloid leukemia as inclusion criteria, 12 are phase 1 (5 open), 6 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), 3 are phase 2/phase 3 (3 open), 3 are phase 3 (2 open), and 4 are no phase specified (2 open) [3].
PMS1 +
PMS1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
PMS2 +
PMS2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
PPM1D +
PPM1D is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
PRDM16 +
PRDM16 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain PRDM16 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
PTPN11 +
PTPN11 is altered in 4.84% of acute myeloid leukemia patients [2].
PTPN11 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTPN11 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
RAD21 +
RAD21 is altered in 2.65% of acute myeloid leukemia patients [2].
RAD21 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RAD21 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
RARA +
RARA is an inclusion eligibility criterion in 37 clinical trials for acute myeloid leukemia, of which 21 are open and 16 are closed. Of the trials that contain RARA status and acute myeloid leukemia as inclusion criteria, 12 are phase 1 (5 open), 6 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), 3 are phase 2/phase 3 (3 open), 3 are phase 3 (2 open), and 4 are no phase specified (2 open) [3].
RET +
RET is altered in 1.24% of acute myeloid leukemia patients [2].
RET is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RET status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
RIT1 +
RIT1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
RPN1 +
RPN1 is an inclusion eligibility criterion in 154 clinical trials for acute myeloid leukemia, of which 116 are open and 38 are closed. Of the trials that contain RPN1 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (2 open), 56 are phase 1 (43 open), 27 are phase 1/phase 2 (19 open), 54 are phase 2 (41 open), 3 are phase 2/phase 3 (2 open), 10 are phase 3 (8 open), and 2 are no phase specified (1 open) [3].
RUNX1 +
RUNX1 is altered in 14.75% of acute myeloid leukemia patients [2].
RUNX1 is an inclusion eligibility criterion in 87 clinical trials for acute myeloid leukemia, of which 49 are open and 38 are closed. Of the trials that contain RUNX1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 29 are phase 1 (11 open), 11 are phase 1/phase 2 (8 open), 28 are phase 2 (18 open), 4 are phase 2/phase 3 (3 open), 8 are phase 3 (6 open), 1 is phase 4 (1 open), and 5 are no phase specified (1 open) [3].
RUNX1T1 +
RUNX1T1 is an inclusion eligibility criterion in 67 clinical trials for acute myeloid leukemia, of which 32 are open and 35 are closed. Of the trials that contain RUNX1T1 status and acute myeloid leukemia as inclusion criteria, 23 are phase 1 (6 open), 9 are phase 1/phase 2 (6 open), 19 are phase 2 (10 open), 3 are phase 2/phase 3 (3 open), 7 are phase 3 (5 open), 1 is phase 4 (1 open), and 5 are no phase specified (1 open) [3].
SF3B1 +
SF3B1 is altered in 3.34% of acute myeloid leukemia patients [2].
SF3B1 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain SF3B1 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].
SH2B3 +
SH2B3 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain SH2B3 status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].
SMARCA4 +
SMARCA4 is altered in 1.77% of acute myeloid leukemia patients [2].
SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
SMARCB1 +
SMARCB1 is altered in 1.95% of acute myeloid leukemia patients [2].
SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
SMC1A +
SMC1A is altered in 1.02% of acute myeloid leukemia patients [2].
SMC1A is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMC1A status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
SMC3 +
SMC3 is altered in 1.27% of acute myeloid leukemia patients [2].
SMC3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMC3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
SRSF2 +
SRSF2 is altered in 10.38% of acute myeloid leukemia patients [2].
SRSF2 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain SRSF2 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].
STAG2 +
STAG2 is altered in 5.88% of acute myeloid leukemia patients [2].
STAG2 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain STAG2 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].
TCF3 +
TCF3 is an inclusion eligibility criterion in 33 clinical trials for acute myeloid leukemia, of which 28 are open and 5 are closed. Of the trials that contain TCF3 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 18 are phase 2 (16 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [3].
TET2 +
TET2 is altered in 16.98% of acute myeloid leukemia patients [2].
TET2 is an inclusion eligibility criterion in 6 clinical trials for acute myeloid leukemia, of which 6 are open and 0 are closed. Of the trials that contain TET2 status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
TP53 +
TP53 is altered in 12.3% of acute myeloid leukemia patients [2].
TP53 is an inclusion eligibility criterion in 110 clinical trials for acute myeloid leukemia, of which 79 are open and 31 are closed. Of the trials that contain TP53 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (2 open), 33 are phase 1 (20 open), 19 are phase 1/phase 2 (14 open), 46 are phase 2 (36 open), 2 are phase 2/phase 3 (1 open), 6 are phase 3 (5 open), and 2 are no phase specified (1 open) [3].
TRA +
TRA is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRA status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TRB +
TRB is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRB status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TRD +
TRD is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRD status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TRG +
TRG is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRG status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
U2AF1 +
U2AF1 is altered in 4.63% of acute myeloid leukemia patients [2].
U2AF1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain U2AF1 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].
WHSC1 +
WHSC1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain WHSC1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
WT1 +
WT1 is altered in 4.29% of acute myeloid leukemia patients [2].
WT1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain WT1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
ZRSR2 +
ZRSR2 is altered in 1.54% of acute myeloid leukemia patients [2].
ZRSR2 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain ZRSR2 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
